Article
Gastroenterology & Hepatology
Mircea Teodor Chiriac, Zsuzsanna Hracsko, Claudia Guenther, Miguel Gonzalez-Acera, Raja Atreya, Iris Stolzer, Leonie Wittner, Anja Dressel, Laura Schickedanz, Reyes Gamez-Belmonte, Lena Erkert, Gheorghe Hundorfean, Sebastian Zundler, Timo Rath, Stefania Vetrano, Silvio Danese, Gregor Sturm, Zlatko Trajanoski, Anja A. Kuehl, Britta Siegmund, Arndt Hartmann, Stefan Wirtz, Jurgen Siebler, Susetta Finotto, Christoph Becker, Markus F. Neurath
Summary: This study aimed to investigate the role of interleukin (IL)-20 in inflammatory bowel disease (IBD) and experimental colitis. The results showed that IL-20 controls colitis and mucosal healing by interfering with the IFN/STAT2 death signalling pathway in intestinal epithelial cells (IECs). These findings provide new directions for suppressing gut inflammation by modulating IL-20-controlled STAT2 signals.
Article
Genetics & Heredity
Qiang Yi, Junfeng Wei, Yangzhou Li
Summary: This study investigated the expressions of miR-103a-3p and TRIM66 in prostate cancer cells and their effects on DTX resistance and glycolysis. The results showed that miR-103a-3p was downregulated and TRIM66 was upregulated in PCa cells. Upregulation of miR-103a-3p and interference with TRIM66 inhibited the proliferation, metastasis, and glycolysis of DTX-resistant cells.
FRONTIERS IN GENETICS
(2022)
Article
Oncology
Hongyan Yu, Mingxu Xie, Zhaoyue Meng, Chun-Yin Lo, Franky Leung Chan, Liwen Jiang, Xiangqi Meng, Xiaoqiang Yao
Summary: Prostate cancer (Pca) is the most common cancer type among males worldwide, with dysregulation of Ca2+ signaling playing important roles during Pca progression. In this study, it was found that MCOLN2 expression is significantly elevated in Pca tissues, promoting Pca development through the IL-1 beta/NF-kappa B pathway. Targeting MCOLN2 could be a potential therapeutic strategy in Pca treatment.
BRITISH JOURNAL OF CANCER
(2021)
Article
Cell Biology
Hongwen Cao, Dan Wang, Peng Sun, Lei Chen, Yigeng Feng, Renjie Gao
Summary: Qi Ling inhibited docetaxel resistance and glycolysis of CRPC possibly via the SNHG10/miR-1271-5p/TRIM66 pathway, showing decreased viability and colony formation, increased apoptosis, and alterations in glucose metabolism in DR cells.
Article
Biochemistry & Molecular Biology
Riaz Jannoo, Zhidao Xia, Paula E. Row, Venkateswarlu Kanamarlapudi
Summary: In this study, the potential of the hybrid lytic peptide (Pep-1-Phor21) to target prostate cancer cells with enhanced IL-13R alpha 2 expression was evaluated. The results showed that Pep-1-Phor21 had a significant cytotoxic effect on both 2D and 3D prostate cancer cells, and treatment with TSA or 5-Aza-dC increased the cells' sensitivity to the lytic peptide in low IL-13R alpha 2 expression cells.
Article
Cell & Tissue Engineering
Feifei Zuo, Junyi Jiang, Haipeng Fu, Kun Yan, Robert Liefke, Jing Zhang, Yaqiang Hong, Zai Chang, Nian Liu, Zhanxin Wang, Qiaoran Xi
Summary: In this study, TRIM66 and DAX1 were identified as negative regulators of the 2C-like state in murine embryonic stem cells. mESCs lacking TRIM66 or DAX1 function showed bidirectional embryonic and extraembryonic differentiation potential. These findings have implications for the practical application of totipotent-like cells.
Article
Oncology
Mircea T. Chiriac, Zsuzsanna Hracsko, Christoph Becker, Markus F. Neurath
Summary: This study investigated the role of the transcription factor STAT2 in colorectal cancer using mouse models and three-dimensional tumoroids. The results showed that STAT2 promotes colorectal cancer through various mechanisms and that anti-cancer drugs can effectively kill tumor cells lacking STAT2. These findings suggest that targeting STAT2-dependent signals could be a potential therapeutic option for colorectal cancer.
Article
Biochemistry & Molecular Biology
Jesse L. Bennett, Brittany N. Jackson, Robert J. Miller, Hoyi Tsui, Miguel Martin-Caraballo
Summary: This study investigated the effects of IL-6 on different types of prostate cancer cells and found that IL-6 can regulate the expression of neuroendocrine markers and calcium channel-related proteins. The effects of IL-6 varied among different cell types.
Review
Immunology
Rosmely Hernandez, Janika Poder, Kathryn M. LaPorte, Thomas R. Malek
Summary: IL-2, the first approved immunotherapy for cancer treatment, not only promotes immunity but also regulates tolerance through regulatory T cells. The crystal structure of IL-2 bound to its receptor has paved the way for the development of engineered IL-2 products.
NATURE REVIEWS IMMUNOLOGY
(2022)
Article
Oncology
Saisai Chen, Kai Lu, Yue Hou, Zonghao You, Chuanjun Shu, Xiaoying Wei, Tiange Wu, Naipeng Shi, Guangyuan Zhang, Jianping Wu, Shuqiu Chen, Lihua Zhang, Wenchao Li, Dingxiao Zhang, Shenghong Ju, Ming Chen, Bin Xu
Summary: The study found that high expression of YY1 is closely associated with M2 macrophages in prostate cancer, promoting tumor development. The study also revealed that treatment targeting YY1 can suppress tumor metastasis and generate synergistic anti-tumor effects. Furthermore, the study revealed that YY1 upregulates IL-6 expression by regulating enhancer-promoter interactions, thereby promoting tumor progression.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Medicine, Research & Experimental
Brendan L. Horton, Alicia D. DSouza, Maria Zagorulya, Chloe McCreery, Gita C. Abhiraman, Lora Picton, Allison Sheen, Yash Agarwal, Noor Momin, K. Dane Wittrup, Forest M. White, K. Christopher Garcia, Stefani Spranger
Summary: Engineered cytokine variants of IL-12 and IL-2 represent a rational approach to combination cytokine therapy for cancer immunotherapy. The combination of IL-12 and IL-2 enhances the effector differentiation of tumor-reactive CD8+ T cells, decreases the number of tumor-infiltrating CD4+ regulatory T cells, and prolongs the survival of lung tumor-bearing mice.
Article
Biochemistry & Molecular Biology
Shreya Kumar, Grace E. Mulia, Marxa L. Figueiredo
Summary: Combination therapy of chemotherapy and immunotherapy shows potential as a novel therapeutic strategy for treating bone-metastatic prostate cancer, with reduced chemotherapy-associated toxicity, enhanced sensitivity to immunotherapy, and improved bone quality.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2023)
Article
Oncology
Zoila A. Lopez-Bujanda, Michael C. Haffner, Matthew G. Chaimowitz, Nivedita Chowdhury, Nicholas J. Venturini, Radhika A. Patel, Aleksandar Obradovic, Corey S. Hansen, Joanna Jackow, Janielle P. Maynard, Karen S. Sfanos, Cory Abate-Shen, Charles J. Bieberich, Paula J. Hurley, Mark J. Selby, Alan J. Korman, Angela M. Christiano, Angelo M. De Marzo, Charles G. Drake
Summary: Castration increases IL-8 expression in prostate epithelial cells, leading to infiltration of tumor-promoting PMN-MDSCs, which can be mitigated by blocking IL-8 signaling. Targeting IL-8 signaling in combination with ICB delays castration resistance and increases polyfunctional CD8 T cell density in tumors.
Article
Biochemistry & Molecular Biology
Jianqiang Zhang, Yuedian Ye, Zhuofan Xu, Mayao Luo, Chenwei Wu, Yifan Zhang, Shidong Lv, Qiang Wei
Summary: KMT2D functions as a critical oncogene in prostate cancer, and its downregulation suppresses cancer progression by inhibiting the IL-6 signaling pathway. Therefore, KMT2D may be considered as a potential new target for prostate cancer therapy.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Article
Chemistry, Multidisciplinary
Deng Wang, Chaping Cheng, Xinyu Chen, Jinming Wang, Kaiyuan Liu, Na Jing, Penghui Xu, Xialian Xi, Yujiao Sun, Zhongzhong Ji, Huifang Zhao, Yuman He, Kai Zhang, Xinxing Du, Baijun Dong, Yuxiang Fang, Pengcheng Zhang, Xueming Qian, Wei Xue, Wei-Qiang Gao, Helen He Zhu
Summary: The activation of androgen receptor (AR) signaling pathway in tumor-associated macrophages (TAMs) promotes the overexpression and secretion of IL-1 beta, inhibiting cytotoxic T cells activation and leading to an immune suppressive microenvironment in advanced prostate cancer (PCa). Combined treatment of androgen deprivation therapy (ADT) with anti-IL-1 beta antibody and immune checkpoint inhibitor anti-PD-1 antibody shows a stronger anticancer effect on castration-resistant PCa.
Article
Pharmacology & Pharmacy
Hongwen Cao, Yigeng Feng, Lei Chen
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
(2017)
Article
Urology & Nephrology
Lei Chen, Hongwen Cao, Yigeng Feng
WORLD JOURNAL OF UROLOGY
(2018)
Article
Integrative & Complementary Medicine
Ying Jian, Zhou Min-jie, Chen Hai-yong, Chen Lei, Zhang Wei, Ji Jun, Yu Chao, Zhang Zhang-jin
CHINESE JOURNAL OF INTEGRATIVE MEDICINE
(2019)
Article
Pharmacology & Pharmacy
Lei Chen, Hongwen Cao, Chao Yu, Yigeng Feng
FUNDAMENTAL & CLINICAL PHARMACOLOGY
(2018)
Article
Genetics & Heredity
Hongwen Cao, Renjie Gao, Chao Yu, Lei Chen, Yigeng Feng
FUNCTIONAL & INTEGRATIVE GENOMICS
(2019)
Article
Pharmacology & Pharmacy
Hongwen Cao, Yigeng Feng, Lei Chen, Chao Yu
Article
Oncology
Xia Yan, Miao Li, Lei Chen, Xiao Peng, Zu-Jun Que, Hong-Mei An, Ke-Ping Shen, Bing Hu
Article
Biochemistry & Molecular Biology
Hongwen Cao, Dan Wang, Renjie Gao, Lei Chen, Yigeng Feng
Summary: The study investigates the role of U2AF1 in prostate cancer resistance to anti-androgen treatment, revealing a negative correlation with ARV7 and poor prognosis in patients. U2AF1 downregulation promotes prostate cancer cell proliferation and bicalutamide resistance by regulating ARV7 splicing.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Chemistry, Medicinal
Jia-Lu Zheng, Shuang-Shuang Wang, Ke-Ping Shen, Xiao-Wei Huang, Miao Li, Lei Chen, Xiao Peng, Hong-Mei An, Bing Hu
Article
Medicine, Research & Experimental
Chao Yu, Hongwen Cao, Xiaofeng He, Peng Sun, Yigeng Feng, Lei Chen, Hua Gong
BIOMEDICINE & PHARMACOTHERAPY
(2017)
Article
Oncology
Hongwen Cao, Hongjie Yu, Yigeng Feng, Lei Chen, Fang Liang
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2017)